Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 19/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10292857 | 0.91 | SLC16A1 (0.49) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL3827762 | 0.90 | SLC16A1 (0.49) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL7935749 | 0.88 | SLC16A1 (0.48) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL3826819 | 0.86 | SLC16A1 (0.49) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL4804153 | 0.82 | SLC16A1 (0.56) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL3830716 | 0.81 | SLC16A1 (0.53) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL3828120 | 0.81 | SLC16A1 (0.66) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL5096845 | 0.81 | SLC16A1 (0.67) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL3829809 | 0.80 | SLC16A1 (0.78) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL3833822 | 0.80 | SLC16A1 (0.50) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8415469-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | SLC16A1 3634/4885CYP2C9 4746/4885CYP3A4 4658/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | SLC16A1 3634/4885CYP2C9 4746/4885CYP3A4 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.